Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$6.96B |
| 2 |
Salesforce
CRM
|
+$2.62B |
| 3 |
UnitedHealth
UNH
|
+$2.16B |
| 4 |
Meta Platforms (Facebook)
META
|
+$2.12B |
| 5 |
Boeing
BA
|
+$1.8B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$8.99B |
| 2 |
GE Aerospace
GE
|
+$5.58B |
| 3 |
Abbott
ABT
|
+$2.84B |
| 4 |
Micron Technology
MU
|
+$1.85B |
| 5 |
Canadian Natural Resources
CNQ
|
+$1.73B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.1% |
| 2 | Healthcare | 15.12% |
| 3 | Industrials | 12.22% |
| 4 | Consumer Discretionary | 11.82% |
| 5 | Communication Services | 9.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
BridgeBio Pharma
BBIO
$16.4B
| $56M | 0.01% |
2,212,085
| – | – |
|
327
Bristol-Myers Squibb
BMY
$130B
| $55.7M | 0.01% |
+1,341,776
| New | +$60M |
|
328
Shell
SHEL
$249B
| $55.4M | 0.01% |
767,922
-1,245,862
| -62% | -$89M |
|
|
AZPN
329
DELISTED
Aspen Technology Inc
AZPN
| $53.5M | 0.01% |
269,467
-24,311
| -8% | -$5M |
|
330
Trex
TREX
$5.05B
| $52.3M | 0.01% |
705,297
| – | – |
|
331
Vista Energy
VIST
$7.31B
| $52.1M | 0.01% |
1,145,694
-85,713
| -7% | -$3.79M |
|
332
MKS Inc
MKSI
$20.7B
| $50.6M | 0.01% |
387,153
| – | – |
|
333
Globant
GLOB
$1.67B
| $49.9M | 0.01% |
279,745
+133,181
| +91% | +$23.5M |
|
334
Delta Air Lines
DAL
$59.1B
| $49.4M | 0.01% |
+1,042,213
| New | +$51.9M |
|
335
ManpowerGroup
MAN
$2.61B
| $47M | 0.01% |
673,630
-253,734
| -27% | -$18.8M |
|
336
Starbucks
SBUX
$124B
| $46.5M | 0.01% |
597,459
+708
| +0.1% | +$57.7K |
|
337
Establishment Labs
ESTA
$2.25B
| $45.5M | 0.01% |
1,000,744
+99,212
| +11% | +$5.03M |
|
338
Hilltop Holdings
HTH
$2.25B
| $45.4M | 0.01% |
1,450,000
-800,000
| -36% | -$24.3M |
|
339
AT&T
T
$166B
| $45.1M | 0.01% |
2,360,169
+24,882
| +1% | +$433K |
|
340
Qualcomm
QCOM
$171B
| $45M | 0.01% |
+225,964
| New | +$42.7M |
|
341
Installed Building Products
IBP
$6.46B
| $44.9M | 0.01% |
218,259
| – | – |
|
|
CHX
342
DELISTED
ChampionX
CHX
| $44.6M | 0.01% |
1,344,115
-681,379
| -34% | -$23.2M |
|
343
Mattel
MAT
$4.19B
| $43.9M | 0.01% |
2,700,000
-3,400,000
| -56% | -$61.6M |
|
344
Camping World
CWH
$659M
| $43.7M | 0.01% |
2,447,542
+288,505
| +13% | +$6.08M |
|
345
Cabot Corp
CBT
$4.46B
| $42.5M | 0.01% |
462,691
-58,795
| -11% | -$5.7M |
|
|
AVDX
346
DELISTED
AvidXchange
AVDX
| $42.5M | 0.01% |
3,523,875
+213,240
| +6% | +$2.43M |
|
347
Pfizer
PFE
$150B
| $42.2M | 0.01% |
1,507,603
| – | – |
|
348
Freshpet
FRPT
$3.48B
| $41.8M | 0.01% |
323,005
| – | – |
|
349
NXP Semiconductors
NXPI
$58.9B
| $41.1M | 0.01% |
152,632
-691,640
| -82% | -$178M |
|
350
Helmerich & Payne
HP
$4.29B
| $39.7M | 0.01% |
1,099,207
-146,061
| -12% | -$5.62M |
|
Similar funds
Capital Research Global Investors's Q2 2024 Portfolio in Review
As of Q2 2024, Capital Research Global Investors held 450 positions worth $456B, up 3.1% from $442B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Capital Research Global Investors's Q2 2024 filing shows 40 new, 179 increased, 147 reduced and 36 closed positions. Its largest new stake was Oracle: 11,571,987 shares worth $1.63B. The largest sale was Broadcom, an estimated $8.99B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Industrials.
- Capital Research Global Investors's largest Q2 2024 buy was Oracle: 11,571,987 shares worth $1.63B.
- Capital Research Global Investors added most to Apple in Q2 2024, an estimated $6.96B increase.
- Capital Research Global Investors's biggest Q2 2024 reduction was Broadcom, cutting an estimated $8.99B.
- Capital Research Global Investors fully exited Norwegian Cruise Line in Q2 2024, selling an estimated $1.19B.
- Capital Research Global Investors's ten largest holdings make up 34% of its $456B portfolio in Q2 2024.
- Capital Research Global Investors opened 40 new positions and closed 36 in Q2 2024.
- Capital Research Global Investors's portfolio value rose 3.1% quarter-over-quarter to $456B.
Based on Capital Research Global Investors's 13F filing for Q2 2024, filed 13 Aug 2024.